BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Aug 12, 2025 • 14min
Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease
CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs. The lead program for APOL1-Mediated Kidney Disease is in phase 2, and a second for PKU and Chronic Kidney Disease will have important healthy volunteer proof of concept data this quarter.
Aug 7, 2025 • 13min
Astria Therapeutics licensed its HAE treatment, Navenibart, to Kaken Pharmaceutical for the Japanese market. It is a kallikrein inhibitor that is in phase 3, and is dosed up to every six months
President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments. Plus, discussing the company's OX40 antagonist for atopic dermatitis that will have key healthy volunteer proof of concept data in the third quarter of this year.
Aug 7, 2025 • 19min
AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions
Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how CureWise is meant to help patients. Its goal is to start with a diversity of opinions from multiple sources and help them converge on a diagnosis.
Aug 5, 2025 • 19min
From Indianapolis: Serial entrepreneur Derek Small publicly launched a new neuroscience company with $90M earlier this summer, Syndeio Biosciences. He tells us about it and talks Indiana biotech.
He discusses the idea behind Syndeio, which focuses on synaptic function and has a lead program in major depressive disorder. Plus, other work he is doing, and Derek's take on the growth and maturity of the biotech ecosystem in Indiana.
Aug 5, 2025 • 6min
From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat
CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it is like working from the IBRI in Indianapolis and being an Indiana biotech company.
Aug 5, 2025 • 9min
The Indiana Biosciences Research Institute is a central hub for the biotech scene in Indiana - its CEO describes what it is all about, and the status of biotech here today
IBRI CEO Alan Palkowitz descrbies the work that takes place at the IBRI, which includes both the institute's own research and how it acts as an incubator to biotech companies. Plus, the state of biotech in Indiana and what its strengths are here.
Aug 4, 2025 • 11min
BiotechTV visits Indiana University School of Medicine's Stark Neurosciences Research Institute and discusses the latest in Alzheimer's research with its executive director, Bruce Lamb
Dr. Lamb, a noted expert in neuroscience and Alzheimer's research, introduces us to Stark and describes the investment in people and equipment that has been made here. The institute has two key focuses of 1) modeling Alzheimer's disease and 2) how to expedite research understandings to treat it. Plus, he discusses a company he has co-founded, called Monument Biosciences, that is focusing on the neuroinflamatory side of the disease.
Jul 30, 2025 • 26min
Former NIH Director and Co-Founder of ModeX Therapeutics Elias Zerhouni shares his take on possible NIH cuts and the state of science in the United States, and working on multispecifics at his company
He highlights his new memoir, Disease Knows No Politics, and gives his opinion on what is at stake in preserving NIH and other scientific funding. Plus, how ModeX is working on multispecifics for cancer and autoimmune conditions, and multivalent vaccines.
Jul 25, 2025 • 10min
AI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient
He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an increasing important tool in precision medicine.
Jul 24, 2025 • 19min
Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders
The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications. Dr. Warmuth walks us through the pipeline progress and overall strategy of finding and pursuing targets.
